SCHEDULE 13G/A: T. Rowe Price Associates Discloses 4.7% Passive Stake in MoonLake Immunotherapeutics
Beneficial Ownership Disclosure
T. Rowe Price Associates, Inc. has filed an amended Schedule 13G, disclosing a 4.7% passive beneficial ownership stake in MoonLake Immunotherapeutics as of March 31, 2025.
Summary
- T. Rowe Price Associates, Inc. reported beneficial ownership of 2,974,271 shares of MoonLake Immunotherapeutics common stock.
- This ownership represents 4.7% of the total class of securities.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- T. Rowe Price Associates, Inc. holds sole voting power over 2,939,443 shares and sole dispositive power over 2,973,785 shares.
Sentiment
Score: 5
Explanation: This is a routine disclosure of passive beneficial ownership by an institutional investor, providing no specific positive or negative sentiment regarding the issuer's performance or outlook. It is a factual reporting of a stake.
Positives
- The disclosure of a significant stake by a reputable institutional investor like T. Rowe Price Associates, Inc. may signal a degree of confidence in MoonLake Immunotherapeutics' long-term prospects.
Negatives
- No negative information is disclosed in this routine ownership filing.
Risks
- This Schedule 13G filing does not contain information regarding the specific risks associated with MoonLake Immunotherapeutics' operations or financial performance.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding MoonLake Immunotherapeutics' future outlook.
Industry Context
This filing is a standard disclosure of an institutional investor's passive stake in a publicly traded company. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact that a major asset manager has invested in MoonLake Immunotherapeutics.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and the presence of a significant institutional investor in MoonLake Immunotherapeutics.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement, indicating the ownership snapshot. |
| 05/14/2025 | Date the Schedule 13G Amendment No. 1 was signed by T. Rowe Price Associates, Inc. |
Keywords
MoonLake Immunotherapeutics, T. Rowe Price Associates, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.